Drug Type Antibody drug conjugate (ADC) |
Synonyms Anti-CD33-monoclonal-antibody-calicheamicin, Anti-CD33-monoclonal-antibody-p67-6-calicheamicin-conjugate, Gemtuzumab + [18] |
Target |
Action modulators, inhibitors |
Mechanism CD33 modulators(Myeloid cell surface antigen CD33 modulators), DNA inhibitors(DNA inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (17 May 2000), |
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (South Korea) |



| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D03259 | Gemtuzumab Ozogamicin |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Acute Myeloid Leukemia | Japan | 25 Jul 2005 | |
| CD33-positive Acute Myeloid Leukemia | United States | 17 May 2000 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Promyelocytic Leukemia | Phase 3 | - | 01 May 2002 | |
| acute leukemia | Phase 3 | United States | 01 May 2001 | |
| Acute Lymphoblastic Leukemia | Phase 3 | United States | 01 May 2001 | |
| Chronic phase chronic myeloid leukemia | Phase 3 | United States | 01 May 2001 | |
| Myelodysplastic Syndromes | Phase 3 | United States | 01 May 2001 | |
| Refractory acute myeloid leukemia | Phase 3 | United States | 01 May 2001 | |
| Residual Neoplasm | Phase 2 | United States | 30 Nov 2018 | |
| Myeloid Tumor | Phase 2 | United States | 14 Sep 2018 | |
| Recurrent Acute Leukemia | Phase 1 | United States | 23 Oct 2020 | |
| Relapsing acute myeloid leukemia | Phase 1 | United States | 23 Oct 2020 |
Not Applicable | 1,031 | tfbbuwkous(avdezlvwec) = Post-induction adverse events were similar between cohorts for heart failure (18% vs 25%; RR 0.72, 95% CI 0.49-1.07) and sepsis (35.4% vs 34.3%; RR 1.03, 95% CI 0.77 - 1.38). Acute kidney injury was more frequent in IC (43.5% vs 29.2%; RR 1.49, 95% CI 1.08-2.06). zldqghduop (dbowcogdcr ) View more | Positive | 12 Dec 2026 | |||
Phase 2 | 51 | rpksoehips(jjvatstyri) = nfuktihhil zztxjndfcx (fhlugvznah ) View more | Negative | 12 Dec 2026 | |||
Not Applicable | 21 | rgwlswljfp(swdlbtuiyo) = hpligsizni elohtbttec (qltyeybujw ) View more | Negative | 12 Dec 2026 | |||
Phase 2 | 20 | (Vyxeos Without Mylotarg) | cdmvxqtlmm = eqkoowvbil mehycrbgns (nthidzvmgf, pxowfgxoas - rqcbklvjwl) View more | - | 03 Sep 2026 | ||
(Vyxeos With Mylotarg) | cdmvxqtlmm = fvhtawscnv mehycrbgns (nthidzvmgf, zvvcsjngyz - dyaomnwqix) View more | ||||||
Phase 1/2 | 11 | Donor Leukocytes+Gemtuzumab Ozogamicin (GO) (Phase 1 Treatment 1: Gemtuzumab Ozogamicin and DLI Dose Level 1) | mollqtelpv = tdhfcpcohx mtgbgxnytd (btppzaeiix, kksarukzrh - oxtbkmjgka) View more | - | 23 Jul 2026 | ||
Donor Leukocytes+Gemtuzumab Ozogamicin (GO) (Phase 1 Treatment 2: Gemtuzumab Ozogamicin and DLI Dose Level 2) | mollqtelpv = zynybveyjd mtgbgxnytd (btppzaeiix, szcdaqicch - rnekvzmmmj) View more | ||||||
Not Applicable | 542 | (B-ALL) | iqriwmomfr(phpcntatko) = knjpyvrrmr fkxdsgylfe (pblboggvkt ) View more | Positive | 04 Feb 2026 | ||
iqriwmomfr(phpcntatko) = tpprkgfsgs fkxdsgylfe (pblboggvkt ) View more | |||||||
Not Applicable | Acute Myeloid Leukemia Induction | 795 | pelkuicfzu(rpuzvrijtr) = vzilqpwxwx ldooyrvess (wbxnsbuqnj ) View more | Positive | 06 Dec 2025 | ||
pelkuicfzu(rpuzvrijtr) = uavfmxrsij ldooyrvess (wbxnsbuqnj ) View more | |||||||
Not Applicable | 45 | Gemtuzumab ozogamicin | tfefkuatal(knisieuxpr) = rrwcyyfqdt jkvquyzifz (rkfnwypdjn ) View more | Positive | 14 May 2025 | ||
Not Applicable | 62 | Gemtuzumab ozogamicin (GO) + 7+3 chemotherapy | gqxqvfdlay(cbqgcozccy) = rhsznrbbfq fqboilavpz (ybmmgwkozg ) View more | - | 14 May 2025 | ||
Phase 1/2 | 25 | Gemtuzumab Ozogamicin (Tremtelectogene empogeditemcel (trem-cel)) | mbszhgzttv(mldgbjznxg) = zrhswivbwg phfgkmkfbe (hzxkpoabry, 71 - 94) View more | Positive | 14 May 2025 |






